2 August 2017

Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update

LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that it will…

Read more

18 May 2017

Verona Pharma Announces Closing of Exercise of Underwriters’ Over-allotment Option

LONDON, May 18, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signific…

Read more

2 May 2017

Verona Pharma Announces Closing of Global Offering

LONDON, May 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signific…

Read more

26 April 2017

Verona Pharma Announces Pricing of Global Offering and Approval to List on the NASDAQ Global Market

5 April 2017

[ENCRYPTED]

[ENCRYPTED]

Read more

4 April 2017

Verona Pharma Doses First Patient in Phase 2a Clinical Trial Evaluating RPL554 for Cystic Fibrosis

Read more

4 April 2017

Verona Pharma Files Registration Statement for Proposed Global Offering

Read more

20 March 2017

2016 Annual Report and Accounts and Notice of AGM

Read more

8 February 2017

Result of General Meeting Consolidation of Share Capital

Read more

18 January 2017

Proposed new Articles for adoption at Meeting on 8 February 2017

Read more

Innovative Therapies for Respiratory Care

See the 2017 Verona Pharma corporate video 2017

Runtime: 04:05

Go

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us